Call for Abstract

4th International Conference and Exhibition on Biologics and Biosimilars, will be organized around the theme “The future of next generation Biologics and Biosimilars”

Biosimilars 2015 is comprised of 14 tracks and 94 sessions designed to offer comprehensive sessions that address current issues in Biosimilars 2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Current concepts of drugs and biologics
  • Track 1-2Unique considerations for biologics
  • Track 1-3Early clinical development essentials
  • Track 1-4Late clinical development essentials
  • Track 1-5Drug Safety essentials
  • Track 1-6Advertising, promotion and labeling  essentials
  • Track 1-7Cancer therapeutics
  • Track 1-8Comparability for Biologics
  • Track 2-1Biosimilars China
  • Track 2-2Biosimilars India
  • Track 2-3Biosimilars USA
  • Track 2-4Biosimilars Europe
  • Track 3-1Current problems in pharmacovigilance
  • Track 3-2Role of pharma industries in the improvement of pharmacovigilance system
  • Track 3-3Detection and evaluation of drug safety signals
  • Track 3-4Adverse drug reactions with pharmaceutical products
  • Track 3-5Good pharmacovigilance practice and pharmacoepidemiology
  • Track 4-1Pharma Patent Scenario
  • Track 4-2Criteria for Patentability and Patent Claims
  • Track 4-3Critical research issues
  • Track 4-4Patentable subject matter
  • Track 4-5Recent Patent disputes and litigations
  • Track 5-1Licensing of biosimilars
  • Track 5-2Biosimilars regulation
  • Track 5-3Patent issues
  • Track 5-4BLA filing for biosimilars
  • Track 5-5Regulatory prospects of BRIC countries
  • Track 5-6A paradigm of traditional generics to biosimilars
  • Track 5-7Biowaiver approval for Biosimilars
  • Track 5-8Generic Biosimilars
  • Track 6-1Recombinant blood products
  • Track 6-2Biosimilars interferon
  • Track 6-3Biosimilar monoclonal antibodies
  • Track 6-4Biosimilars in cancer treatment
  • Track 6-5Recombinant therapeutic proteins
  • Track 6-6Biosimilar peptides
  • Track 6-7Insulin Biosimilars
  • Track 6-8Growth hormones
  • Track 6-9Recombinant vaccines
  • Track 6-10Biosimilars in rheumatic diseases
  • Track 7-1Biosimilars Clinical Trials
  • Track 7-2Toxicological studies
  • Track 7-3Clinical PK/PD studies
  • Track 7-4 Targeted cell line development
  • Track 7-5Transgenic animals
  • Track 7-6Case studies, and clinical models
  • Track 7-7Risk management, and quality affairs
  • Track 7-8Clinical trials on major diseases
  • Track 7-9Biosimilars Clinical Studies
  • Track 7-10Aspects of genotoxicity tests
  • Track 8-1Biologics in diabetes
  • Track 8-2EBiologics in autoimmune disease
  • Track 8-3Biologics in cardivascular diseases
  • Track 8-4Biologics in digestive disorders
  • Track 8-5Biologics in genetic disorders
  • Track 8-6Biologics in neurologic disorders
  • Track 8-7Biologics in respiratory disorders
  • Track 8-8Biologics for Psoriasis
  • Track 8-9Biologics In Cancer
  • Track 9-1Global impact of biosimilars over generics
  • Track 9-2Economic aspect towards biosimilars
  • Track 9-3Biosimilars in global market
  • Track 9-4Investment and returns on biosimilars
  • Track 9-5Cost and risk management
  • Track 9-6Adopting innovative mechanisms such as risk-sharing arrangement
  • Track 9-7European market for biosimilars
  • Track 9-8Global P&R models for the biosimilars and generics market
  • Track 10-1Biotechnology medicinal products for different drugs
  • Track 10-2Challenges faced in developing biosimilars
  • Track 10-3Future of next generation biosimilars
  • Track 10-4Biopharmaceuticals development
  • Track 11-1Biosimilar Bioanalytical methods
  • Track 11-2Biosimilar Formulation
  • Track 11-3Bioassay for comparability and potency testing
  • Track 11-4Biosimilar GMP protein analysis
  • Track 11-5Biosimilar LC/MS analysis for discovery, preclinical, and clinical programs
  • Track 11-6Biosimilar Electrophoresis
  • Track 11-7Biosimilar Multimodal techniques
  • Track 12-1Strategies for the bioequivalence assessment of topical dosage forms
  • Track 12-2Bioequivalence assessment of respiratory dosage forms
  • Track 12-3Bioequivalence approaches for transdermal dosage forms
  • Track 12-4Evaluation of highly variable drugs and drug products
  • Track 13-1BCS biowaivers
  • Track 13-2Preclinical and clinical testing for oral drug delivery
  • Track 13-3Waiver for In vivo bioavailability or bioequivalence
  • Track 13-4Consideration of biowaiver extensions for BCS class III drugs
  • Track 13-5In vitro diffusion cells for dissolution testing in formulation development
  • Track 13-6Dissolution testing in drug formulation
  • Track 13-7In vitro preclinical ADME/BCS testing
  • Track 13-8In vitro drug product research
  • Track 14-1Transgenic plants
  • Track 14-2Post translational genetics
  • Track 14-3Fermentation culture
  • Track 14-4Molecular farming